Navann Ty

what are you seeing in IVF cycles across the U.S., EMEA and APAC?

if you could discuss MiSight, again, solid performance in light of the Stellest entering the market.

can you please clarify the driver of the expected Q4 rebound? Was that driven by the upcoming year of the horse?

is that in anticipation of that new competitor? Or is PARAGARD losing share versus organisms in plants

have the updated end-of-life strategy and refocused sales force being fully implemented in Q3

If you could discuss recent M&A environment in Hologic three segments

I'm curious whether the sales force has communicated to customers in future that the FNA expansion was imminent

should we still expect 2025 margin expansion to be still gross margin-led?

if you can discuss further the underlying factors embedded in the 2% decline, expected midpoint in terms of macro impact

your pricing strategy to defend against the competitive pressure in derms, which is further intensifying

would you say that the competition is now not only on price, but also some efficacy in frontline use as well

if you could quantify maybe how much is due to distributor inventory dynamics versus the competitive pressure from Zenrelia and NUMELVI in Europe

do you still expect approval of the long-acting OA Pain this year? And how is the dialogue with the FDA and/or the EC?

Do you expect to pivot back to accessing the moderate population in the US at some point?

can you discuss the new FINTEP-one indication for Simparica Trio versus Elanco’s Credelio and Quattro?

If you can comment on the blockbuster potential of the expected approvals that you have listed?

can you discuss any expected impact of the US label changes, if any, on the transition to the moderate population in the US?